TeaRx Overview

  • Founded
  • 2011
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Investors
  • 3

TeaRx General Information


Developer of novel therapeutic drugs created to prevent deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing orthopedic and general surgery. The company's flagship drug product, Tearexaban, is the representative of a new class of anticoagulants- blood coagulation factor Xa inhibitors and has TRX1 molecule which is expected to have significant competitive advantages, enabling researchers to prevent thromboembolism.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Building 1, Rabochaya Street
  • Khimki 2-d
  • Moscow, 141400
  • Russia
+7 8 (000) 000-00-00
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TeaRx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC Completed Clinical Trials - General

TeaRx Executive Team (2)

Name Title Board Seat Contact Info
Nikolay Savchuk Chairman

1 Former Executive

TeaRx Board Members (1)

Name Representing Role Since
Nikolay Savchuk Self Chairman 000 0000

TeaRx Investors (3)

To view TeaRx‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioLight Life Sciences Corporation Minority 000 0000 000000 0
ChemRar Ventures Venture Capital Minority 000 0000 000000 0
Torrey Pines Investment Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial